Patrick Spence
Family · Columbus, OHNPI 1548504624
Payments from drug & device makers
Across 222 payments — averaging $29.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- Viiv Healthcare Company$935
- AbbVie$563
- Novo Nordisk$246
- Janssen Products, LP$224
- Lilly USA, LLC$170
- plus $1K from 22 others
What the payments were for
- Consulting fees$1,57024%
- Travel & lodging$300%
- Food & beverage$4,79874%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 56 | $3,095 |
| Viiv Healthcare Company | 40 | $935 |
| AbbVie | 36 | $563 |
| Novo Nordisk | 21 | $246 |
| Janssen Products, LP | 2 | $224 |
| Lilly USA, LLC | 10 | $170 |
| AstraZeneca | 11 | $168 |
| Stryker | 1 | $159 |
| Merck | 8 | $155 |
| Exact Sciences | 5 | $133 |
| Johnson & Johnson(2 entities) | 5 | $119 |
| Napo Pharmaceuticals Inc | 4 | $90 |
| Bayer | 4 | $66 |
| Boehringer Ingelheim | 3 | $64 |
| Abbott | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Shionogi Inc | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Verity Pharmaceuticals Inc. | 1 | $21 |
| Amgen | 1 | $20 |
| GSK | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| EMD Serono, Inc. | 1 | $19 |
| Lucid Diagnostics Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Dynavax Technologies Corporation | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,498 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 53 | $263,415 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 65 | $256,900 |
| OzempicSemaglutide | 84 | $82,910 |
| TrulicityDulaglutide | 74 | $81,085 |
| DovatoDolutegravir Sodium/Lamivudine | 24 | $74,697 |
| DescovyEmtricitabine/Tenofov Alafenam | 23 | $49,836 |
| JardianceEmpagliflozin | 46 | $49,279 |
| JulucaDolutegravir/Rilpivirine | 11 | $36,161 |
| EliquisApixaban | 32 | $35,755 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 12 | $32,314 |
| FarxigaDapagliflozin Propanediol | 37 | $24,027 |
| LinzessLinaclotide | 23 | $17,129 |
| TradjentaLinagliptin | 17 | $14,454 |
| JanuviaSitagliptin Phosphate | 15 | $12,645 |
| Arnuity ElliptaFluticasone Furoate | 29 | $8,115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $3,095 | $306,73688 claims |
| Janssen Products, LPSymtuza | $224 | $263,41553 claims |
| Viiv Healthcare CompanyDovato, Juluca | $935 | $110,85735 claims |
| Novo NordiskOzempic | $246 | $82,91084 claims |
| Lilly USA, LLCTrulicity, Humulin N | $170 | $82,58885 claims |
| Boehringer IngelheimJardiance, Tradjenta | $64 | $63,73263 claims |
| MerckDelstrigo, Januvia | $155 | $44,96027 claims |
| AstraZenecaFarxiga, Symbicort | $168 | $29,13156 claims |
| AbbVieLinzess | $563 | $17,12923 claims |
| GSKArnuity Ellipta | $20 | $8,11529 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $5,98511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Columbus
- Christina GastColumbus$66K
- Beth LoessinColumbus$34K
- Mary HurleyColumbus$15K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.